Drug-Drug Interaction Potential of Orbactiv (Oritavancin) Co-Administered With Warfarin in Healthy Subjects

NCT02340988 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Single-Dose IV Oritavancin Diphosphate and Warfarin
DRUG: Single-Dose IV Oritavancin Diphosphate and Warfarin 24 hour post dose

Sponsor

Melinta Therapeutics, Inc.